Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.71 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.71 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.71 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.71 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.71 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.71 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.71 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.71 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.71 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.71 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.71 |
| ▸ | CSNK1D | P48730 | 5/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.69 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.69 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.69 |
| ▸ | RELA | Q04206 | 2/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.68 |
| ▸ | ACP1 | P24666 | 1/20 | 0.68 |
| ▸ | NCS1 | P62166 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5313704 | 0.84 | CSNK1D (0.69) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL4858014 | 0.84 | CSNK1D (0.69) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL29485044 | 0.84 | DYRK1A (0.69) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL29282910 | 0.84 | DYRK1A (0.69) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Ethylene SCHEMBL8167289 | 0.84 | CSNK1D (0.69) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL29485043 | 0.84 | DYRK1A (0.69) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL6206186 | 0.84 | RAB9A (0.72) | CSNK1DSMN1; SMN2NFKB1NFKB2RELA | |
| Hydrochloric Acid SCHEMBL25333657 | 0.83 | CSNK1D (0.68) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL3933070 | 0.83 | DYRK1A (0.72) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL5070926 | 0.83 | POLB (0.76) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200354374-A1 | Chemical Entities, Pharmaceutical Formulations, and Methods for Treating Fibrosis | Inspira, LLC | 2020-11-12 | — | — | US | disclosed |
| US-20110190285-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | ABSOLUTE SCIENCE, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110034521-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-02-10 | — | — | US | disclosed |
| WO-2010033360-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | 1/3 ABSOLUTE SCIENCE, INC. (US) | 2010-03-25 | — | — | WO | disclosed |
| WO-2009045761-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | ABSOLUTE SCIENCE, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034521-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | MMP7, MMP3, MMP9 | HDAC3 242/4885HDAC4 401/4885HDAC1 137/4885 |
| US-20110190285-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | NPY5R, RAC3, CPA3 | HDAC3 4202/4885HDAC4 3185/4885HDAC1 4782/4885 |
| US-20200354374-A1 | Chemical Entities, Pharmaceutical Formulations, and Methods for Treating Fibrosis | CFTR, FIBP, ABCC1 | HDAC3 668/4885HDAC4 2480/4885HDAC1 1727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.